No Data Yet
Altimmune's stock (ALT) increased by 16.52% after the U.S. FDA granted Breakthrough Therapy Designation to its MASH drug candidate, pemvidutide, on January 6, 2026.
Altimmune announced the 48-week topline results from its IMPACT Phase IIb trial for the MASH treatment pemvidutide on December 19, 2025.